Pathogenic role of iL-6 combined with TNF-α or iL-1 in the induction of acute phase proteins SAA and CRP in chronic inflammatory diseases

Advances in Experimental Medicine and Biology

Volumn 691, Issue , 2011, Pages 141-150

  Yoshizaki, Kazuyuki ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; CHEMOKINE; CYTOKINE; ETANERCEPT; HEPATOCYTE NUCLEAR FACTOR 1; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; JANUS KINASE; MESSENGER RNA; PROTEIN C FOS; PROTEIN C JUN; SERUM AMYLOID A; STAT3 PROTEIN; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; CLINICAL FEATURE; CONFERENCE PAPER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY DISEASE; JUVENILE RHEUMATOID ARTHRITIS; LABORATORY TEST; PATHOGENESIS; PHYSICIAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN INDUCTION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; ARTICLE; BIOLOGICAL MODEL; CELL STRAIN HEPG2; CHRONIC DISEASE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; INFLAMMATION; METABOLISM; PATHOLOGY;

ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; CHRONIC DISEASE; GENE EXPRESSION REGULATION; HEP G2 CELLS; HUMANS; INFLAMMATION; INTERLEUKIN-1; INTERLEUKIN-6; MODELS, BIOLOGICAL; RNA, MESSENGER; SERUM AMYLOID A PROTEIN; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79954429910     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-6612-4_15     Document Type: Conference Paper

References (14)

1. Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T, Kishimoto T, Yoshizaki K (2000) Improvement in Castelman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95:56-61
2. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, Nakano N, Ikeda Y, Sasaki T, Nishioka K, Hara M, Taguchi H, Kimura Y, Kato Y, Asaoku H, Kumagai S, Kodama F, Nakahara H, Hagihara K, Yoshizaki K, Kishimoto T (2005) Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman's disease. Blood 106:2627-2632
3. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J, Azuma J, Kishimoto T (2004) Treatment of rheumatoid arthritis with humanized antiinterleukin- 6 receptor antibody: A multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 50(6):1761-1769
4. Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M, Woo P, Nishimoto N, Yoshizaki K, Kishimoto T (2005) Therapeutic efficacy of humanized recombinant antiinterleukin- 6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 52(3):818-825
5. Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, Breedveld FC, Smolen JS, Eberl G, deWoody K, Feldmann M, Maini RN (1999) Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 163(3):1521-1528
6. Hagihara K, Nishikawa T, Isobe T, Song J, Sugamata Y, Yoshizaki K (2004) IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun 314(2):363-369
7. Betts JC, Cheshire JK, Akira S, Kishimoto T, Woo P (1993) The role of NF-kappa B and NF-IL6 transactivating factors in the synergistic activation of human serum amyloid A gene expression by interleukin-1 and interleukin-6. J Biol Chem 268(34):25624-256231
8. Hagihara K, Nishikawa T, Sugamata Y, Song J, Isobe T, Taga T, Yoshizaki K. Essential role of STAT3 in cytokine-driven NF-kappaB-mediated serum amyloid A gene expression. Genes Cells. 2005:1051-63
9. Nakashima K, Yanagisawa M, Arakawa H, Kimura N, Hisatsune T, Kawabata M, Miyazono K, Taga T (1999) Synergistic signaling in fetal brain by STAT3-Smad1 complex bridged by p300. Science 284(5413):479-482
10. Zhang D, Sun M, Samols D, Kushner I (1996) STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6. J Biol Chem 271(16):9503-9509
11. Toniatti C, Demartis A, Monaci P, Nicosia A, Ciliberto G (1990) Synergistic trans-activation of the human C-reactive protein promoter by transcription factor HNF-1 binding at two distinct sites. EMBO J 9(13):4467-4475
12. Nishikawa T, Hagihara K, Serada S, Isobe T, Matsumura A, Song J, Tanaka T, Kawase I, Naka T, Yoshizaki K (2008) Transcriptional complex formation of c-Fos, STAT3, and hepatocyte NF-1 alpha is essential for cytokine-driven C-reactive protein gene expression. J Immunol 180(5):3492-3501
13. Zhang X, Wrzeszczynska MH, Horvath CM, Darnell JE Jr (1999) Interacting regions in Stat3 and c-Jun that participate in cooperative transcriptional activation. Mol Cell Biol 19(10):7138-7146
14. Leu JI, Crissey MA, Leu JP, Ciliberto G, Taub R (2001) Interleukin-6-induced STAT3 and AP-1 amplify hepatocyte nuclear factor 1-mediated transactivation of hepatic genes, an adaptive response to liver injury. Mol Cell Biol 21(2):414-424